Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives.
PD-1/PD-L1 axis
cancer immune tolerance
extracellular vesicles (EVs)
immune checkpoints
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Mar 2020
26 Mar 2020
Historique:
received:
27
02
2020
revised:
17
03
2020
accepted:
23
03
2020
entrez:
1
4
2020
pubmed:
1
4
2020
medline:
17
12
2020
Statut:
epublish
Résumé
The modulation of the immune system is one of the hallmarks of cancer. It is now widely described that cancer cells are able to evade the immune response and thus establish immune tolerance. The exploration of the mechanisms underlying this ability of cancer cells has always attracted the scientific community and is the basis for the development of new promising cancer therapies. Recent evidence has highlighted how extracellular vesicles (EVs) represent a mechanism by which cancer cells promote immune escape by inducing phenotypic changes on different immune cell populations. In this review, we will discuss the recent findings on the role of tumor-derived extracellular vesicles (TEVs) in regulating immune checkpoints, focusing on the PD-L1/PD-1 axis.
Identifiants
pubmed: 32225076
pii: ijms21072286
doi: 10.3390/ijms21072286
pmc: PMC7177226
pii:
doi:
Substances chimiques
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Int J Cancer. 2019 Oct 15;145(8):2209-2224
pubmed: 30980673
Med Oncol. 2011 Sep;28(3):682-8
pubmed: 20373055
PLoS One. 2010 Jul 22;5(7):e11469
pubmed: 20661468
Proteomics. 2019 Apr;19(8):e1800158
pubmed: 30893511
Mem Inst Oswaldo Cruz. 2014 Feb;109(1):70-9
pubmed: 24141959
Br J Cancer. 2007 Sep 3;97(5):637-45
pubmed: 17667919
Cell Res. 2018 Aug;28(8):862-864
pubmed: 29959401
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Drug Des Devel Ther. 2015 Feb 16;9:901-9
pubmed: 25733810
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Cancer Res. 2012 Oct 1;72(19):4920-30
pubmed: 22865453
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Curr Opin Immunol. 2013 Apr;25(2):214-21
pubmed: 23298609
Expert Opin Biol Ther. 2010 Nov;10(11):1573-86
pubmed: 20955112
Nat Cell Biol. 2010 Jan;12(1):19-30; sup pp 1-13
pubmed: 19966785
Cell Death Dis. 2019 Nov 4;10(11):829
pubmed: 31685807
Oncogene. 2018 Aug;37(31):4239-4259
pubmed: 29713056
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Annu Rev Immunol. 2003;21:685-711
pubmed: 12615891
Mol Cancer. 2019 Apr 3;18(1):78
pubmed: 30943982
Int J Cancer. 2019 Jun 15;144(12):3111-3126
pubmed: 30536597
J Transl Med. 2019 Oct 29;17(1):355
pubmed: 31665020
Adv Cancer Res. 2004;92:13-27
pubmed: 15530555
Cancers (Basel). 2019 Jun 22;11(6):
pubmed: 31234517
Oncoimmunology. 2018 Jan 16;7(4):e1412909
pubmed: 29632728
Immunol Lett. 2018 Jul;199:36-43
pubmed: 29800589
Front Immunol. 2017 Jun 28;8:760
pubmed: 28702032
Cancer Immunol Res. 2018 Dec;6(12):1578-1592
pubmed: 30396909
Mod Pathol. 2016 Sep;29(9):1104-12
pubmed: 27198569
J Clin Invest. 2010 Feb;120(2):457-71
pubmed: 20093776
Front Immunol. 2019 Jul 12;10:1563
pubmed: 31354719
Lancet Oncol. 2018 Jul;19(7):940-952
pubmed: 29875066
Immunity. 2010 Oct 29;33(4):464-78
pubmed: 21029958
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Cancer Res. 2019 Sep 15;79(18):4715-4728
pubmed: 31337655
Nat Rev Immunol. 2013 Apr;13(4):227-42
pubmed: 23470321
Sci Immunol. 2017 Jul 28;2(13):
pubmed: 28754746
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
Nat Commun. 2019 Jul 5;10(1):3000
pubmed: 31278254
Exp Mol Pathol. 2014 Jun;96(3):284-91
pubmed: 24657498
Neurosurgery. 2018 Sep 1;83(3):E98-E100
pubmed: 30125027
J Immunol. 2019 Dec 15;203(12):3447-3460
pubmed: 31704881
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Exp Mol Med. 2019 Aug 9;51(8):1-13
pubmed: 31399559
Lancet Oncol. 2018 Jan;19(1):51-64
pubmed: 29217288
Immunity. 2018 Mar 20;48(3):434-452
pubmed: 29562194
J Immunol. 2008 Jun 1;180(11):7249-58
pubmed: 18490724
EMBO J. 1992 Nov;11(11):3887-95
pubmed: 1396582
Trends Mol Med. 2005 Aug;11(8):362-9
pubmed: 16002337
Clin Cancer Res. 2018 Feb 15;24(4):896-905
pubmed: 29233903
Nat Commun. 2017 Jan 09;8:14041
pubmed: 28067230
Int J Mol Sci. 2019 Jul 05;20(13):
pubmed: 31284422
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Nat Rev Immunol. 2004 May;4(5):336-47
pubmed: 15122199
Oncotarget. 2014 Jul 30;5(14):5439-52
pubmed: 24978137
Science. 1990 Jun 15;248(4961):1349-56
pubmed: 2113314
J Neurooncol. 2015 Apr;122(2):293-301
pubmed: 25579983
Nat Rev Immunol. 2003 Jun;3(6):454-62
pubmed: 12776205
Annu Rev Immunol. 2003;21:305-34
pubmed: 12471050
J Immunother Cancer. 2017 Aug 15;5(1):65
pubmed: 28806909
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Acta Histochem. 2006;108(1):19-24
pubmed: 16530813
Neoplasia. 2006 Mar;8(3):190-8
pubmed: 16611412
Leukemia. 2012 Sep;26(9):2019-26
pubmed: 22446501
Front Immunol. 2019 Jul 19;10:1719
pubmed: 31379886
J Cell Biol. 2013 Feb 18;200(4):373-83
pubmed: 23420871
Cancer Biol Ther. 2019;20(5):583-592
pubmed: 30739532
Asian Pac J Cancer Prev. 2013;14(1):309-14
pubmed: 23534743
Adv Sci (Weinh). 2019 Oct 23;6(24):1901779
pubmed: 31871860
Nat Rev Immunol. 2002 Feb;2(2):116-26
pubmed: 11910893
Nature. 2011 Jul 13;475(7355):226-30
pubmed: 21753853
J Cancer Res Clin Oncol. 2008 Sep;134(9):1021-7
pubmed: 18347814
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Cell Immunol. 1996 Dec 15;174(2):116-28
pubmed: 8954611
J Cancer. 2013;4(1):36-44
pubmed: 23386903
Annu Rev Immunol. 2006;24:175-208
pubmed: 16551247
Cancer Manag Res. 2019 May 06;11:4023-4040
pubmed: 31190980
Front Immunol. 2018 Apr 11;9:730
pubmed: 29696022
Lancet Oncol. 2017 Dec;18(12):1600-1609
pubmed: 29129441
Oncoimmunology. 2017 Jul 19;6(8):e1261243
pubmed: 28919985
Ann Oncol. 2014 Oct;25(10):1935-40
pubmed: 25009014
Front Immunol. 2017 Dec 04;8:1597
pubmed: 29255458
J Immunol. 2007 Jun 1;178(11):6867-75
pubmed: 17513735
Oral Oncol. 2018 Jan;76:34-41
pubmed: 29290284
N Engl J Med. 2015 May 21;372(21):2006-17
pubmed: 25891304
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Immunity. 2004 Aug;21(2):137-48
pubmed: 15308095
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Clin Cancer Res. 2015 Mar 1;21(5):1071-7
pubmed: 25538263
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Front Immunol. 2019 Oct 15;10:2453
pubmed: 31681327
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Mol Cancer. 2019 Oct 23;18(1):146
pubmed: 31647023
Mol Cancer. 2015 Aug 14;14:155
pubmed: 26272696
Nat Rev Immunol. 2003 Dec;3(12):939-51
pubmed: 14647476
Immunol Cell Biol. 2002 Apr;80(2):131-7
pubmed: 11940113
Sci Rep. 2018 Aug 10;8(1):11972
pubmed: 30097593
J Natl Cancer Inst. 2017 Jan 28;109(6):
pubmed: 28131992
Crit Rev Oncol Hematol. 2014 Jan;89(1):140-65
pubmed: 24029602
Neuro Oncol. 2020 Feb 21;:
pubmed: 32080744
Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7
pubmed: 16916931
Blood. 2005 Feb 15;105(4):1815-22
pubmed: 15494428
Oncogene. 2019 Jun;38(26):5158-5173
pubmed: 30872795
J Extracell Vesicles. 2017 Sep 26;6(1):1378056
pubmed: 29184623
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
J Clin Oncol. 2019 Jun 10;37(17):1470-1478
pubmed: 30943124
Oncogene. 2017 Aug 17;36(33):4692-4705
pubmed: 28394344
Mol Cell Biol. 2005 Nov;25(21):9543-53
pubmed: 16227604
Ann Med. 1995 Oct;27(5):537-41
pubmed: 8541028
J Immunol. 2004 Jul 15;173(2):945-54
pubmed: 15240681
N Engl J Med. 2015 Sep 24;373(13):1270-1
pubmed: 26398076
J Immunol. 2009 Sep 15;183(6):3720-30
pubmed: 19692638
Clin Cancer Res. 2016 Jun 15;22(12):3057-66
pubmed: 26763253
J Biol Chem. 2013 Apr 12;288(15):10849-59
pubmed: 23439645
J Hematol Oncol. 2019 Aug 22;12(1):84
pubmed: 31438991
Genes Cancer. 2018 May;9(5-6):176-189
pubmed: 30603054
Oncol Rep. 2017 Aug;38(2):785-798
pubmed: 28656228
Oncogenesis. 2018 May 25;7(5):41
pubmed: 29799520
J Pathol. 2016 Jun;239(2):162-73
pubmed: 26956697
Dev Cell. 2019 May 6;49(3):347-360
pubmed: 31063754
JAMA Oncol. 2017 Sep 14;3(9):e172411
pubmed: 28817753
Haematologica. 2011 Sep;96(9):1302-9
pubmed: 21606166
Oncotarget. 2016 May 10;7(19):27033-43
pubmed: 27081032
Oncoimmunology. 2019 Apr 24;8(7):1593805
pubmed: 31143513
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
Cell. 2014 Oct 23;159(3):499-513
pubmed: 25417103
Oncoimmunology. 2015 Mar 2;4(6):e1008347
pubmed: 26155415
Curr Opin Immunol. 2014 Apr;27:1-7
pubmed: 24413387
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
Sci Rep. 2016 Feb 04;6:20254
pubmed: 26842680
Nat Med. 2007 Jan;13(1):84-8
pubmed: 17159987
Expert Opin Investig Drugs. 2010 Jan;19(1):77-91
pubmed: 20001556
J Cell Mol Med. 2019 Feb;23(2):1257-1267
pubmed: 30456891
J Thorac Oncol. 2016 Jul;11(7):976-88
pubmed: 26944305
Sci Adv. 2018 Mar 07;4(3):eaar2766
pubmed: 29532035
Cell. 2001 Aug 10;106(3):255-8
pubmed: 11509172
Annu Rev Cell Dev Biol. 2014;30:255-89
pubmed: 25288114
Comput Struct Biotechnol J. 2018 Nov 22;17:1-13
pubmed: 30581539
Gene. 2018 Nov 15;676:101-109
pubmed: 30010038
Mol Cancer Res. 2017 Jan;15(1):93-105
pubmed: 27760843
Cancer Immunol Res. 2014 Nov;2(11):1023-33
pubmed: 25367977
Int J Cancer. 2009 Jun 1;124(11):2621-33
pubmed: 19235923
Curr Opin Immunol. 2010 Apr;22(2):231-7
pubmed: 20144856
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Cell. 2019 Apr 4;177(2):414-427.e13
pubmed: 30951669
J Dig Dis. 2017 Oct;18(10):574-581
pubmed: 28851046
J Immunol. 2017 Aug 15;199(4):1505-1515
pubmed: 28696255
Anticancer Res. 2010 Sep;30(9):3747-57
pubmed: 20944164
Cell. 2017 Nov 30;171(6):1301-1315.e14
pubmed: 29195074
Cancer Invest. 2013 Jun;31(5):330-5
pubmed: 23614656
Nat Cell Biol. 2015 Jun;17(6):816-26
pubmed: 25985394